Peripheral blood stem cell transplants for multiple myeloma: identification of favorable variables for rapid engraftment in 225 patients, Blood, vol.85, issue.2, pp.588-96, 1995. ,
Multiple Myeloma, New England Journal of Medicine, vol.364, issue.11, pp.1046-1060, 2011. ,
DOI : 10.1056/NEJMra1011442
URL : https://hal.archives-ouvertes.fr/hal-01282339
Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with non-intensive therapy; analysis of the Phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone, Blood, vol.116, pp.3743-50, 2010. ,
Bortezomib Plus Dexamethasone Is Superior to Vincristine Plus Doxorubicin Plus Dexamethasone As Induction Treatment Prior to Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: Results of the IFM 2005-01 Phase III Trial, Journal of Clinical Oncology, vol.28, issue.30, pp.4621-4629, 2010. ,
DOI : 10.1200/JCO.2009.27.9158
Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group. Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study, Blood, vol.120, issue.8, 2012. ,
Bortezomib-Based Versus Non-bortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials, J Clin Oncol, issue.26, pp.31-3279, 2013. ,
Multiple myeloma: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up, Ann Oncol, vol.24, pp.133-137, 2013. ,
Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myeloma, Leukemia, vol.366, issue.11, pp.2242-2244, 2013. ,
DOI : 10.1056/NEJMoa1114138
HIGH-DOSE INTRAVENOUS MELPHALAN FOR PLASMA-CELL LEUKAEMIA AND MYELOMA, The Lancet, vol.322, issue.8354, pp.822-824, 1983. ,
DOI : 10.1016/S0140-6736(83)90739-0
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma, New England Journal of Medicine, vol.348, issue.19, pp.1875-1883, 2003. ,
DOI : 10.1056/NEJMoa022340
Improving stem cell mobilization strategies: future directions, Bone Marrow Transplantation, vol.93, issue.3, pp.181-95, 2009. ,
DOI : 10.1016/j.bbmt.2007.03.007
URL : http://www.nature.com/bmt/journal/v43/n3/pdf/bmt2008410a.pdf
Treatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answers, Haematologica, vol.99, issue.3, pp.408-424, 2014. ,
DOI : 10.3324/haematol.2013.096149
Autologous haematopoietic stem cell mobilisation in multiple myeloma and lymphoma patients: a position statement from the European Group for Blood and Marrow Transplantation, Bone Marrow Transplantation, vol.54, issue.7, pp.865-72, 2014. ,
DOI : 10.1038/bmt.2011.82
AMD3100 plus G-CSF can successfully mobilize CD341 cells from ,
Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data, Bone Marrow Transplant, vol.41, issue.4, pp.331-338, 2008. ,
3101 Investigators. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma, J Clin Oncol, vol.27, issue.28, pp.4767-4773, 2009. ,
versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma, Blood, vol.113, issue.23, pp.5720-5726, 2009. ,
The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF, Bone Marrow Transplantation, vol.45, issue.3, pp.356-363, 2011. ,
DOI : 10.1038/sj.bmt.1703729
Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation, Biol Blood Marrow Transplant, vol.14, issue.9, pp.1045-1056, 2008. ,
Kinetics of blood CD34+ cells after chemotherapy plus G-CSF in poor mobilizers: Implications for pre-emptive plerixafor use, Annals of Hematology, vol.15, issue.7, pp.1073-1079, 2012. ,
DOI : 10.3109/10428194.2011.578312
A nationwide survey of the use of plerixafor in patients with lymphoid malignancies who mobilize poorly demonstrates the predominant use of the ???on-demand??? scheme of administration at French autologous hematopoietic stem cell transplant programs, Transfusion, vol.49, issue.9, pp.2149-2157, 2015. ,
DOI : 10.1038/bmt.2014.39
Plerixafor is effective given either preemptively or as a rescue strategy in poor stem cell mobilizing patients with multiple myeloma, Transfusion, vol.14, issue.2, pp.275-283, 2015. ,
DOI : 10.3109/14653249.2011.652733
Plerixafor as preemptive strategy results in high success rates in autologous stem cell mobilization failure, Journal of Clinical Apheresis, vol.53, issue.2, pp.1-11, 2017. ,
DOI : 10.1111/j.1537-2995.2012.03848.x
Comparison of engraftment following different stem cell mobilization modalities in patients with multiple myeloma treated with a uniform induction regimen containing bortezomib, cyclophosphamide and dexamethasone, Annals of Hematology, vol.26, issue.Suppl 6, pp.461-467, 2017. ,
DOI : 10.1038/leu.2011.197
Is there a standard-of-care for transfusion support of patients with haematological malignancies?, Current Opinion in Hematology, vol.24, issue.6, pp.1-6, 2017. ,
DOI : 10.1097/MOH.0000000000000377
Relationship of CD34+ cell dose to early and late hematopoiesis following autologous peripheral blood stem cell transplantation, Bone Marrow Transplantation, vol.19, issue.4, pp.303-313, 1997. ,
DOI : 10.1038/sj.bmt.1700671
Therapeutic Relevance of CD34 Cell Dose in Blood Cell Transplantation for Cancer Therapy, Journal of Clinical Oncology, vol.18, issue.6, pp.1360-77, 2000. ,
DOI : 10.1200/JCO.2000.18.6.1360
Predictive factors for long-term engraftment of autologous blood stem cells, Bone Marrow Transplantation, vol.4, issue.12, pp.1299-304, 2000. ,
DOI : 10.1038/2023
Cell Dose Positively Affects the Time to Hematopoietic Recovery and Supportive Requirements after High-Dose Chemotherapy, Hematology, vol.84, issue.5, pp.195-209, 1999. ,
DOI : 10.1200/JCO.1995.13.8.1922
Importance of blood graft characteristics in auto-SCT: implications for optimizing mobilization regimens, Bone Marrow Transplantation, vol.14, issue.5, pp.627-662, 2011. ,
DOI : 10.3109/10428190009065829
Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective, Bone Marrow Transplantation, vol.112, issue.7, pp.886-91, 2015. ,
DOI : 10.1182/blood-2007-12-130179
URL : http://www.nature.com/bmt/journal/v50/n7/pdf/bmt2014330a.pdf
Higher Infused Lymphocyte Dose Predicts Higher Lymphocyte Recovery, Which in Turn, Predicts Superior Overall Survival following Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma, Biology of Blood and Marrow Transplantation, vol.14, issue.1, pp.116-140, 2008. ,
DOI : 10.1016/j.bbmt.2007.08.051
Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma, Blood, vol.98, issue.3, pp.579-85, 2001. ,
DOI : 10.1182/blood.V98.3.579
URL : http://www.bloodjournal.org/content/bloodjournal/98/3/579.full.pdf